Trials / Completed
CompletedNCT02981524
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
A Phase 2 Study of GVAX Colon Vaccine (With Cyclophosphamide) and Pembrolizumab in Patients With Mismatch Repair-Proficient (MMR-p) Advanced Colorectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study will be looking at the objective response rate (ORR) as measured by RECIST in in patients with mismatch repair-proficient (MMR-p), advanced colorectal cancer that treated with CY/GVAX in combination with Pembrolizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CY | CY is administered intravenously at 200 mg/m2 |
| BIOLOGICAL | GVAX | GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting |
| DRUG | Pembrolizumab | Pembrolizumab is administered intravenously at 200 mg |
Timeline
- Start date
- 2017-05-26
- Primary completion
- 2018-03-20
- Completion
- 2018-03-20
- First posted
- 2016-12-05
- Last updated
- 2021-02-10
- Results posted
- 2019-10-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02981524. Inclusion in this directory is not an endorsement.